Primate

Zymeworks Presents New Data from Multiple Preclinical Development Programs at 2024 American Association for Cancer Research Annual Meeting

Retrieved on: 
Monday, April 8, 2024
Well, Small-cell carcinoma, Therapeutic index, Glomus tumor, Endometrial cancer, Survival, Environment, Service provider, Trichloroethylene, Patient, Primate, Triple-negative breast cancer, Lead, Zymeworks, 3D, Standard of care, Cancer, TAA, Spacecraft, Lung cancer, IND, CD3, DLL3, AACR, Workflow, Antibody, TCE, CD28, Therapy, Stomach, ADC, Vaccine

The compelling preclinical activity profile supports ZW191 development across multiple tumor types, including FRα-high/mid/low ovarian cancers and other FRα-expressing indications, including non-small cell lung cancer, endometrial cancer, and triple-negative breast cancer.

Key Points: 
  • The compelling preclinical activity profile supports ZW191 development across multiple tumor types, including FRα-high/mid/low ovarian cancers and other FRα-expressing indications, including non-small cell lung cancer, endometrial cancer, and triple-negative breast cancer.
  • An investigational new drug (IND) submission or foreign equivalent is planned for 2024.
  • Small cell lung cancer (SCLC) is an aggressive neuroendocrine cancer with a poor prognosis and high unmet medical need2.
  • Displays no cross-linking of T cells and exhibits obligate cis T cell binding of CD28, requiring co-engagement of CD3.

CHARLES RIVER ALERT: Bragar Eagel & Squire, P.C. is Investigating Charles River Laboratories International, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

Retrieved on: 
Wednesday, April 3, 2024
Risk, Telephone, Primate, Defendant, Complaint, CRL, Research, P.C

NEW YORK, April 02, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Charles River Laboratories International, Inc. (NYSE: CRL) on behalf of long-term stockholders following a class action complaint that was filed against Charles River on May 19, 2023 with a Class Period from May 5, 2020 to February 21, 2023.

Key Points: 
  • NEW YORK, April 02, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Charles River Laboratories International, Inc. (NYSE: CRL) on behalf of long-term stockholders following a class action complaint that was filed against Charles River on May 19, 2023 with a Class Period from May 5, 2020 to February 21, 2023.
  • Our investigation concerns whether the board of directors of Charles River have breached their fiduciary duties to the company.
  • According to the complaint, throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects.
  • There is no cost or obligation to you.

Vincerx Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Update

Retrieved on: 
Friday, March 29, 2024
Patient, PTCL, G&A, IND, Prednisone, Neoplasm, Therapy, SMDC, Medicinal chemistry, Lymphoma, Research, Frontiers Media, RNA polymerase II, Body modification, Primate, RNA, NIH, CPT, Potential, Safety, CDK9, ADC, MCL1, Solubility, Oncogene, RNA polymerase, Venetoclax, Journal, Manuscript, Cancer, Peripheral T-cell lymphoma, AACR, Antibody, MYC, Downregulation and upregulation, DLBCL, Annual general meeting, HER2, European Hematology Association, EHA, Spacecraft, PDX, Bangladesh Technical Education Board, Journal of Medicinal Chemistry, Blood, Pharmaceutical industry

PALO ALTO, Calif., March 29, 2024 (GLOBE NEWSWIRE) --  Vincerx Pharma, Inc. (Nasdaq: VINC), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through paradigm-shifting therapeutics, today reported financial results for the fourth quarter and full year ended December 31, 2023, and provided a corporate update.

Key Points: 
  • Vincerx presented preclinical data at the 2023 AACR Annual Meeting demonstrating significant activity in patient-derived xenograft (PDX) lymphoma mouse models.
  • Vincerx shared preclinical data at the 2023 ASH Annual Meeting showing superior activity and safety compared with commercially available B-cell targeted ADCs.
  • For the fourth quarter and full year 2023, Vincerx reported a net loss of $4.9 million, or $0.23 per share, and a net loss of $40.2 million, or $1.89 per share, respectively.
  • For the fourth quarter and full year 2022, Vincerx reported a net loss of $13.8 million, or $0.65 per share, and a net loss of $63.0 million, or $3.00 per share, respectively.

Dyadic Reports 2023 Full Year Results and Recent Company Progress

Retrieved on: 
Thursday, March 28, 2024
Cygnus, Enzyme, Rabies, SAHPRA, Biology, Sale, Innovation, Infection, Note, European, AVATAR, Therapy, Host cell protein, Vaccine, Analysis, Convertible, Research, Biotechnology, A-DNA, Massachusetts General Hospital, Partnership, Melamaravakkadu, Webcast, Primate, RNA, Biofuel, C1, Virology, SME, Safety, Nature Communications, Transferrin, Livestock, Global health, Manuscript, Food, Senior, NIIMBL, Antibody, Hospital, Antigen, Diagnosis, Health, Pithing, RBD, Phibro Animal Health, COVID-19, Dyadic, Messenger, Protein, Human

“In 2023, Dyadic achieved significant milestones in unlocking the potential of its microbial platforms.

Key Points: 
  • “In 2023, Dyadic achieved significant milestones in unlocking the potential of its microbial platforms.
  • We believe that we are well-positioned, both financially and scientifically, to execute our strategic plan with enhanced capabilities and resources.
  • For the year ended December 31, 2023, the Company received a total of approximately $1.3 million in connection with the sale of Alphazyme LLC.
  • Other Income: For the year ended December 31, 2023, the Company had a gain of approximately $1,018,000 from the sale of the Company’s equity interest in Alphazyme, LLC.

IMUNON Reports 2023 Financial Results and Provides Business Update

Retrieved on: 
Thursday, March 28, 2024
Transfer, Ovarian cancer, Immunotherapy, Patient, Lung, Vaccine, Good manufacturing practice, Sale, CMC, IND, Bangladesh Technical Education Board, IPR, Investment, Clinical trial, Neoplasm, Research, Primate, DNA, NOL, MD Anderson Cancer Center, Trial of the century, ITT, Safety, MRD, Interim, Silicon Valley Bank, Vaccination, Food, CMOS, Elsevier, CD8, Drug discovery, SVB, CRS, University, Death, SARS-CoV-2, Earnings call, Lassa mammarenavirus, PFS, Immunoglobulin G, FDA, OS, CD4, Temperature, Progression-free survival, COVID-19, Mouse, Messenger, Human, Wistar Institute, Hospital

LAWRENCEVILLE, N.J., March 28, 2024 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage drug-development company focused on developing DNA-mediated immuno-oncology therapies and next-generation vaccines, today reported financial results for the year ended December 31, 2023. The Company also provided an update on its clinical development programs with IMNN-001, a DNA-based interleukin-12 (IL-12) immunotherapy in Phase 2 clinical development for the treatment of first-line, locally advanced-stage ovarian cancer, and on its PlaCCine modality, a proprietary mono- or multi-cistronic DNA plasmid and a synthetic DNA delivery technology for the expression of pathogen antigens in preclinical studies for the development of next-generation vaccines.

Key Points: 
  • “We remain on track to report topline results mid-year from the OVATION 2 Study with IMNN-001 in advanced ovarian cancer.
  • In September 2023, the Company announced interim PFS and OS data with IMNN-001 in its OVATION 2 Study.
  • The Company is hosting a conference call to provide a business update, discuss 2023 financial results and answer questions at 10:00 a.m. Eastern time today.
  • To participate in the call, please dial 866-777-2509 (Toll-Free/North America) or 412-317-5413 (International/Toll) and ask for the IMUNON 2023 Earnings Call.

Metagenomi Reports Business Updates and Full Year 2023 Financial Results

Retrieved on: 
Wednesday, March 27, 2024
Research, Dicarboxylic acid, AAV, Enzyme, Development, Gene editing, CAST, Cardiovascular disease, Haemophilia, Vivisection, Patient, Primate, RNA, DNA, Wave 1, Sale, Metagenomics, G&A, IPO, Ultra, Doctor of Philosophy, Protein, MBA, Genome, SMART, Factor VIII, CRISPR, Amyloidosis, MGX, AGT, Liver, LNP, Ionis, PAM, Vaccine

EMERYVILLE, Calif., March 27, 2024 (GLOBE NEWSWIRE) -- Metagenomi, Inc. (Nasdaq: MGX), a precision genetic medicines company committed to developing curative therapeutics for patients using its proprietary, comprehensive metagenomics-derived gene editing toolbox, today reported financial results for the full year ended December 31, 2023, and additional business updates.

Key Points: 
  • The aggregate gross proceeds to Metagenomi from the offering were approximately $93.75 million, before deducting underwriting discounts and commissions and offering expenses.
  • In addition, cash used to fund our operations was $91.4 million for the year ended December 31, 2023.
  • R&D Expenses: Research and development (R&D) expenses were $94.4 million for the full year ended December 31, 2023.
  • G&A Expenses: General and administrative (G&A) expenses were $28.8 million for the full year ended December 31, 2023.

Kelonia Therapeutics to Present Preclinical Data Highlighting Therapeutic Potential of in vivo CAR-T Cell Therapy in Multiple Myeloma

Retrieved on: 
Tuesday, April 2, 2024
Biotechnology, Health, Genetics, Pharmaceutical, Oncology, CD4, CD8, Memory, Patient, Primate, Gene, Multiple myeloma, AACR, Therapy, Pharmaceutical industry

Kelonia Therapeutics , a biotech company revolutionizing in vivo gene delivery, today announced new preclinical data from its lead program KLN-1010, which will be presented at the American Association for Cancer Research (AACR) Annual Meeting 2024 in San Diego, California.

Key Points: 
  • Kelonia Therapeutics , a biotech company revolutionizing in vivo gene delivery, today announced new preclinical data from its lead program KLN-1010, which will be presented at the American Association for Cancer Research (AACR) Annual Meeting 2024 in San Diego, California.
  • KLN-1010, a novel, in vivo CAR-T cell therapy candidate for the treatment of multiple myeloma, which leverages the company’s in vivo Gene Placement System (iGPS®) technology, demonstrated that it is safe and effective in preclinical animal models.
  • “These data reinforce the best-in-class potential of our in vivo CAR-T cell therapies,” said Kevin Friedman, Ph.D., Chief Executive Officer and Founder of Kelonia.
  • A single intravenous injection of KLN-1010 displayed potent anti-tumor efficacy and caused complete tumor regression at multiple dose levels in several preclinical animal models.

GreenPan Partners With EARTHDAY.ORG to Plant Over 10,000 Trees in Tanzania Throughout the Month of April

Retrieved on: 
Wednesday, April 3, 2024
Environmental Health, Department Stores, Professional Services, Home Goods, Restaurant, Bar, Other Retail, Natural Resources, Supermarket, Climate Change, Specialty, Food, Beverage, Sustainability, Retail, Environmental, Social and Governance (ESG), Environment, Organic Food, Online Retail, Black-and-white colobus, Canopy, Climate change, Farm, Cyclone, PFAS, Partnership, Education, Primate, Chimpanzee, Flood, Plant, Landslide, Ecology, Tree, Friends

GreenPan is participating in EARTHDAY.ORG’s 2024 The Canopy Project® which plants trees in Tanzania.

Key Points: 
  • GreenPan is participating in EARTHDAY.ORG’s 2024 The Canopy Project® which plants trees in Tanzania.
  • For every order placed during the month of April, GreenPan will plant one tree.
  • The goal is to plant over 10,000 trees throughout the month.
  • EARTHDAY.ORG partnered with a local community organization, Friends of Lake Tanganyika to ensure the project is locally driven and supported.

Precision BioSciences Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Provides Business Update

Retrieved on: 
Wednesday, March 27, 2024
Technology, Biotechnology, FDA, Nanotechnology, Health, Pharmaceutical, Stem Cells, Other Science, Research, Infectious Diseases, Genetics, Fitness & Nutrition, Science, Clinical Trials, Janus, Vivo, Gene editing, Precision BioSciences, Patient, Cash, Mitochondrion, Health care, Infant, NHP, IND, Duchenne muscular dystrophy, Investment, Therapy, ATM, Lilly, Precision, Cell, Skeletal muscle, Hepatitis B, Rachel Haurwitz, Central nervous system, Novartis, Primate, RNA, DNA, Mitochondrial disease, Hepatology, CRISPR, Safety, VWAP, PMM, Food, AAV, Development, Prevail, Publishing, Gene, ASX, University, Diaphragm, OTC, Hemoglobinopathy, IMU, Economics, Administration, Sickle cell disease, PCSK9, CTA, MHRA, Reindeer, Heart, Autoimmune disease, Eli Lilly and Company, DMD

PBGENE-HBV (Viral Elimination Program): Precision is developing PBGENE-HBV for the treatment of patients with chronic hepatitis B.

Key Points: 
  • PBGENE-HBV (Viral Elimination Program): Precision is developing PBGENE-HBV for the treatment of patients with chronic hepatitis B.
  • In November 2023, Precision presented preclinical efficacy and safety data at the 2023 American Association for the Study of Liver Diseases Annual Meeting.
  • Cash and Cash Equivalents: As of December 31, 2023, Precision had $116.7 million in cash and cash equivalents.
  • Revenues: Total revenues for the quarter ended December 31, 2023 were $7.0 million, as compared to $10.6 million for the quarter ended December 31, 2022.

Myeloid Therapeutics to Showcase In Vivo CAR Data and its Diverse mRNA Platform at AACR

Retrieved on: 
Thursday, April 4, 2024
Vivo, Canadian Aviation Regulations, Patient, Primate, RNA, Fragment crystallizable region, Cancer, Messenger, AACR, Chemokine, Cytokine, Drug development, Safety, Myeloid tissue, NK, LNP, Antigen, Annual general meeting, Vaccine

This advancing study represents the first human trial of any in vivo chimeric antigen receptor (CAR) therapy.

Key Points: 
  • This advancing study represents the first human trial of any in vivo chimeric antigen receptor (CAR) therapy.
  • Myeloid will also share information on its portfolio of immune cell programming CARs.
  • "We are thrilled to continue driving this first in vivo mRNA CAR program forward," said Chief Executive Officer Daniel Getts, Ph.D. "Myeloid is at the forefront of in vivo immune cell programming.
  • To date, Myeloid has demonstrated CAR activity in human cells, and following systemic mRNA/LNP delivery in mouse and non-human primates.